In a report released yesterday, Shagun Singh Chadha from RBC Capital maintained a Hold rating on Axonics Modulation Technologies (AXNX – Research Report), with a price target of $71.00. The company’s ...

Axonics Modulation Technologies (AXNX – Research Report) received a Hold rating and price target from Wolfe Research analyst Michael Polark yesterday. The company’s shares closed yesterday at $69.36.

Axonics Modulation Technologies (AXNX) came out with quarterly earnings of $0.13 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.01 per share a year ...

The latest update is out from Axonics Modulation Technologies ( (AXNX)). The merger completed on November 15, 2024, transformed the Company into a wholly owned subsidiary, resulting in its delisting ...

Medical device giant Boston Scientific announced a $3.7 billion deal on Monday to augment its urology portfolio. The company is acquiring Axonics, a maker of neurostimulation devices that treat ...

Weighted-average shares used to compute basic and diluted net loss per share ...

For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Axonics Modulation Technologies (AXNX) is a stock that can ...

IRVINE, Calif.--(BUSINESS WIRE)--Axonics, Inc. (Nasdaq: AXNX), a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel ...

Axonics Modulation Technologies (AXNX) came out with a quarterly loss of $0.89 per share versus the Zacks Consensus Estimate of a loss of $0.73. This compares to loss of $2.67 per share a year ago.

Axonics Modulation Technologies Inc. closed $14.5 million in series C financing, pushing its total fund-raising past the $85 million mark. The Irvine-based medical device company develops rechargeable ...